Host nuclear transcription machinery (acting on the liver-specific F8 expression cassette)

The host nuclear transcription machinery acting on the liver-specific F8 expression cassette refers to the collective cellular proteins in hepatocytes that facilitate the expression of a therapeutic Factor VIII (F8) gene delivered via gene therapy. This machinery includes RNA polymerase II and a suite of liver-specific transcription factors, such as Hepatocyte Nuclear Factor 4 alpha (HNF4α) and CCAAT/enhancer-binding protein (C/EBP), which recognize specific cis-regulatory elements within the gene therapy's promoter [High & Roncarolo, NEJM, 2019]. In patients with Hemophilia A, who lack functional Factor VIII, adeno-associated virus (AAV) vectors are used to deliver a codon-optimized F8 expression cassette to the nucleus of liver cells. The host's transcriptional apparatus hijacks this exogenous DNA to produce functional Factor VIII protein, which is then secreted into the bloodstream to restore hemostasis [Pasi et al., NEJM, 2020]. Drugs targeting this system, such as valoctocogene roxaparvovec, rely on the high efficiency and tissue-specificity of these interactions to achieve therapeutic efficacy while minimizing off-target effects [FDA Roctavian Label, 2023]. Monitoring this process involves measuring circulating Factor VIII activity and assessing liver health through enzyme levels to ensure the host machinery is not compromised by immune responses to the viral vector.

Other names

Hepatocyte transcriptional apparatusLiver-specific F8 expression systemRNA polymerase II transcription complexHost cell machinery for F8 transgene expression

Recruitment of endogenous hepatocyte-specific transcription factors (e.g., HNF4α, C/EBP) and the RNA polymerase II complex to the synthetic promoter and enhancer elements of an AAV-delivered Factor VIII (F8) expression cassette to initiate mRNA synthesis and subsequent protein production [FDA Roctavian Label, 2023; Pasi et al., NEJM, 2020].